MedTrace Logo

The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente

NCT01066650 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1391

Last updated 2015-07-28

No results posted yet for this study

Summary

The TWENTE Study is a single center prospective single-blinded randomized study. Randomization will involve the type of Drug-Eluting Stent (DES) used in study population. Patients will be blinded to the type of DES they will receive. The general practitioner of the patient will be requested not to disclose this information to the patient. Analysts who perform the data analyses will be blinded to the type DES used as well.

Conditions

Interventions

DEVICE

Endeavor Resolute (Biolinx-based Zotarolimus-eluting stent)

Drug eluting Stent

DEVICE

Xience V (Everolimus-eluting stent)

Drug eluting stent

Sponsors & Collaborators

  • Foundation of Cardiovascular Research and Education Enschede

    lead OTHER

Principal Investigators

  • C. von Birgelen, MD,PhD,Prof · Thorax Centrum Twente

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-08-31
Completion
2012-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01066650 on ClinicalTrials.gov